The world’s transition to renewable electricity is bottlenecked by the ability to store energy safely, cheaply, and at high power density. Conventional lithium‑ion batteries (LIBs) have dominated the market for three decades, yet they face three persistent challenges:
While the journey from Phase II to a regulatory green light is fraught with scientific and commercial challenges, the places HMN‑372 among the most promising neuro‑immune candidates in the current pipeline. HMN-372